Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G4RQ
|
||||
| Former ID |
DCL000024
|
||||
| Drug Name |
GSK 796406
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Discontinued in Phase 1 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H40N2O5
|
||||
| Canonical SMILES |
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2<br />)OC)OC)OC
|
||||
| InChI |
1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
|
||||
| InChIKey |
XQLWNAFCTODIRK-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
854012, 5588061, 7979354, 8151048, 10510120, 11120269, 11120757, 11121245, 11121448, 11121928, 11362517, 11365079, 11367641, 11370305, 11370306, 11373242, 11375803, 14834960, 24439579, 26752312, 26752313, 47440013, 47810532, 47885193, 47885194, 48110231, 48258991, 49878993, 50105237, 50105238, 57320831, 76626821, 85087629, 85286057, 85787221, 85788738, 90341545, 91721411, 92309799, 96024702, 99300713, 103235960, 103845994, 103925610, 104171189, 104297146, 117513596, 124749992, 124880746, 124880747
|
||||
| Target and Pathway | |||||
| Target(s) | Angiotensin-converting enzyme | Target Info | Inhibitor | [2] | |
| Neutral endopeptidase | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Renin-angiotensin system | ||||
| Chagas disease (American trypanosomiasis) | |||||
| Hypertrophic cardiomyopathy (HCM)hsa04614:Renin-angiotensin system | |||||
| Hematopoietic cell lineage | |||||
| Protein digestion and absorption | |||||
| Alzheimer's disease | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Angiotensin Metabolism | ||||
| Reactome | Metabolism of Angiotensinogen to AngiotensinsR-HSA-2022377:Metabolism of Angiotensinogen to Angiotensins | ||||
| WikiPathways | ACE Inhibitor Pathway | ||||
| Metabolism of Angiotensinogen to AngiotensinsWP2729:Metabolism of Angiotensinogen to Angiotensins | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Alzheimers Disease | |||||
| References | |||||
| REF 1 | Mechanism of Vasopeptidase Inhibitor-Induced Plasma Extravasation: Comparison of Omapatrilat and the Novel Neutral Endopeptidase 24.11/Angiotensin-Converting Enzyme Inhibitor GW796406. JPET December 2005 vol. 315 no. 3 1306-1313. | ||||
| REF 2 | Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.